To Jonathan Edwards...
Regarding this statement...
"Once one has started [tr]eating someone with rituximab there is no way of putting the clock back. The immune system is altered and permanently so, although in most cases it settles back to normal between treatments."
OK, but isn't this alteration desirable? Also, how is this alteration permanent if the B cells come back? And also, trying not to be cynical, or underestimate the need for specific expertise or patient monitoring, etc., but there are likely many treatments administered by many physicians, who don't understand the mechanisms behind the medications/treatments that they prescribe...they simply prescribe/treat based on the fact that it works.....
Thank you for your contribution to this forum.
No, I am afraid people simply have no idea how complicated this is.
The memory B cells that you accumulate throughout a lifetime somehow manage to ensure that you are protected against all the microbes you were immunised against as a child and also provide a rapid response to any new microbes without also producing autoantibodies. We have no idea exactly how a balanced repertoire is achieved. When we give rituximab we destroy B cells indiscriminately. It is remarkable that it does not seem to lead to much in the way of infection risk. But there is every reason to think that at least in a proportion of people we will be removing useful B cells that one day will be needed. For RA we take that risk because there are major benefits but we do not take the risk lightly. A small number of patients after one course of rituximab never seen to get B cells back at all - after ten years. They are well but we have no idea what the future holds. A small number of patients have a crash in antibody levels - down to less than 10% of normal, and need regular replacement.
So the alteration in B cells is desirable if we are sure there are autoantibodies that will go away. If as in scleroderma the autoantibodies do not budge then the effect is generally undesirable - just negative. If we do not know if there are any autoantibodies, as in ME the effect may be just negative.
And the bit about doctors often not understanding completely misses the point. For nearly all drugs doctors have a reasonable idea what the drug is supposed to do and why you either need to give it just for a week like an antibiotic or for years like insulin. Even the patient normally knows enough to understand why they take anti-hypertensives, hormones, cancer drugs, vitamins etc etc. But the mechanism of action of rituximab in terms of what it is doing to the B cell system is not understood by the vast majority of doctors using it for autoimmunity. Doctors understand why they use it in B cell cancer but not in autoimmunity. That is because immunology is complicated and most rheumatologists, despite dealing with immune diseases, are too lazy to learn enough immunology to understand it. They often think they do but really have no idea. In fact it only makes sense to use rituximab in autoimmunity if your working hypothesis about autoimmunity is the one I published in 1999. Most doctors have either not heard of that or think they know better and believe in something else - and then use rituximab despite it making no sense in terms of their theory.
So in short the chances of a doctor offering rituximab for a condition where autoimmunity is speculated, like ME, knowing what they are doing is close to zero. Fluge and Mella are exceptions because they have read the relevant literature and we have discussed all their findings in comparison with what we found in RA. They are also smart scientists.
It's bit like a comparison between removing a mole and open heart surgery. Most drugs are like removing a mole. Any doctor can do that. Using rituximab isn't.